NASDAQ:DCTH Delcath Systems (DCTH) Stock Price, News & Analysis $8.70 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$8.39▼$8.8250-Day Range$6.45▼$8.8452-Week Range$2.25▼$9.18Volume163,888 shsAverage Volume241,915 shsMarket Capitalization$241.77 millionP/E RatioN/ADividend YieldN/APrice Target$19.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Delcath Systems alerts: Email Address Delcath Systems MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside128.0% Upside$19.83 Price TargetShort InterestBearish5.72% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.31) to ($0.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.05 out of 5 starsMedical Sector634th out of 936 stocksSurgical & Medical Instruments Industry75th out of 101 stocks 3.5 Analyst's Opinion Consensus RatingDelcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDelcath Systems has only been the subject of 3 research reports in the past 90 days.Read more about Delcath Systems' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.72% of the outstanding shares of Delcath Systems have been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Delcath Systems has recently increased by 2.58%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DCTH. Previous Next 2.5 News and Social Media Coverage News SentimentDelcath Systems has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Delcath Systems this week, compared to 2 articles on an average week.Search Interest11 people have searched for DCTH on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have not sold or bought any company stock.Percentage Held by Insiders17.94% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Delcath Systems' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Delcath Systems are expected to grow in the coming year, from ($1.31) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDelcath Systems has a P/B Ratio of 12.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Delcath Systems' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.Get our No. 1 stock (with 500%-plus upside potential) for this rare market event now. About Delcath Systems Stock (NASDAQ:DCTH)Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Read More DCTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DCTH Stock News HeadlinesJuly 22, 2024 | finance.yahoo.comDelcath Systems to Host Second Quarter 2024 Earnings CallJuly 22, 2024 | businesswire.comDelcath Systems to Host Second Quarter 2024 Earnings CallJuly 27, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.July 19, 2024 | barrons.comDelcath Systems Inc.June 13, 2024 | investorplace.comHave $5-10? 7 Affordable Stocks That Are About to Breakout.May 28, 2024 | finance.yahoo.comDelcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath’s Board of DirectorsMay 16, 2024 | markets.businessinsider.comDelcath Systems: Strong Financials and HEPZATO KIT Growth Prompt Buy Rating and Raised Price TargetMay 15, 2024 | finance.yahoo.comDelcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...July 27, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.May 15, 2024 | msn.comStephens & Co. Initiates Coverage of Delcath Systems (DCTH) with Overweight RecommendationMay 14, 2024 | markets.businessinsider.comDelcath Systems Inc. Q1 Loss Beats EstimatesMay 14, 2024 | prnewswire.comDelcath Systems Reports First Quarter 2024 Results and Business HighlightsMay 13, 2024 | markets.businessinsider.comDelcath Systems Poised for Commercial Success with HEPZATO-KIT Launch, Analyst Issues Buy RatingMay 7, 2024 | prnewswire.comDelcath Systems to Host First Quarter 2024 Earnings CallMay 6, 2024 | prnewswire.comPublication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KITMay 3, 2024 | prnewswire.comDelcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | finanznachrichten.deDelcath Systems, Inc.: Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | finance.yahoo.comDelcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Confirmed)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:DCTH CUSIPN/A CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees60Year FoundedN/APrice Target and Rating Average Stock Price Target$19.83 High Stock Price Target$25.00 Low Stock Price Target$13.00 Potential Upside/Downside+128.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,680,000.00 Net Margins-1,080.72% Pretax Margin-1,080.72% Return on Equity-290.07% Return on Assets-111.05% Debt Debt-to-Equity RatioN/A Current Ratio2.52 Quick Ratio2.25 Sales & Book Value Annual Sales$2.07 million Price / Sales116.80 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book12.08Miscellaneous Outstanding Shares27,790,000Free Float22,801,000Market Cap$241.77 million OptionableOptionable Beta0.64 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Gerard J. Michel MBA (Age 61)MS, CEO & Director Comp: $727.97kMs. Sandra Pennell (Age 44)Senior VP of Finance and Principal Financial & Accounting Officer Dr. Martha S. Rook Ph.D. (Age 54)Chief Operating Officer Mr. David HoffmanGeneral Counsel, Corporate Secretary & Chief Compliance OfficerDr. Johnny John M.D. (Age 59)Senior Vice President of Clinical Operations & Medical Affairs Comp: $472.16kDr. Vojislav Vukovic M.D. (Age 57)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsBrainsWayNASDAQ:BWAYApollo EndosurgeryNASDAQ:APENPulse BiosciencesNASDAQ:PLSEPerspective TherapeuticsNYSE:CATXOrthoPediatricsNASDAQ:KIDSView All CompetitorsInsiders & InstitutionsLegato Capital Management LLCBought 115,463 shares on 7/26/2024Ownership: 0.415%Rosalind Advisors Inc.Bought 1,611,561 shares on 7/12/2024Ownership: 9.537%BVF Inc. ILBought 225,918 shares on 5/16/2024Ownership: 4.327%Levin Capital Strategies L.P.Bought 5,969 shares on 5/16/2024Ownership: 0.198%Vanguard Group Inc.Bought 161,678 shares on 5/10/2024Ownership: 2.461%View All Insider TransactionsView All Institutional Transactions DCTH Stock Analysis - Frequently Asked Questions How have DCTH shares performed this year? Delcath Systems' stock was trading at $4.16 on January 1st, 2024. Since then, DCTH stock has increased by 109.1% and is now trading at $8.70. View the best growth stocks for 2024 here. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) posted its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). The firm earned $3.14 million during the quarter, compared to the consensus estimate of $3.70 million. Delcath Systems had a negative net margin of 1,080.72% and a negative trailing twelve-month return on equity of 290.07%. When did Delcath Systems' stock split? Shares of Delcath Systems reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Delcath Systems' major shareholders? Delcath Systems' top institutional investors include Rosalind Advisors Inc. (9.54%) and Legato Capital Management LLC (0.42%). Insiders that own company stock include Gil Aharon, Rosalind Advisors, Inc, Gerard J Michel, Vojo Vukovic, John Purpura, Sandra Pennell, Steven A J Salamon and John Richard Sylvester. View institutional ownership trends. How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DCTH) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Delcath Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
